BACKGROUND: Duration of untreated psychosis (DUP) may contribute to the observed heterogeneity of the treatment response in first-episode schizophrenia. AIMS: To examine the relationship of DUP and premorbid function with clinical outcomes following up to 2 years of antipsychotic treatment. METHOD:For a subsample (n=191) of subjects participating in a clinical trial, DUP and premorbid function were prospectively compared with clinical response to olanzapine or haloperidol. RESULTS: Shorter DUP and good premorbid function each independently are associated with better clinical response, including improvement in overall psychopathology and negative symptoms. Premorbid function also is associated with positive symptom, social and vocational outcomes. CONCLUSIONS: Earlier antipsychotic treatment is associated with better outcomes in first-episode schizophrenia. Poor premorbid function could indicate an illness subtype less likely to respond to antipsychotic treatment regardless of when it is instituted.
RCT Entities:
BACKGROUND: Duration of untreated psychosis (DUP) may contribute to the observed heterogeneity of the treatment response in first-episode schizophrenia. AIMS: To examine the relationship of DUP and premorbid function with clinical outcomes following up to 2 years of antipsychotic treatment. METHOD: For a subsample (n=191) of subjects participating in a clinical trial, DUP and premorbid function were prospectively compared with clinical response to olanzapine or haloperidol. RESULTS: Shorter DUP and good premorbid function each independently are associated with better clinical response, including improvement in overall psychopathology and negative symptoms. Premorbid function also is associated with positive symptom, social and vocational outcomes. CONCLUSIONS: Earlier antipsychotic treatment is associated with better outcomes in first-episode schizophrenia. Poor premorbid function could indicate an illness subtype less likely to respond to antipsychotic treatment regardless of when it is instituted.
Authors: Juan A Gallego; Delbert G Robinson; Serge M Sevy; Barbara Napolitano; Joanne McCormack; Martin L Lesser; John M Kane Journal: J Clin Psychiatry Date: 2011-09-06 Impact factor: 4.384
Authors: Ashwinee Manivannan; William Foran; Maria Jalbrzikowski; Vishnu P Murty; Gretchen L Haas; Goda Tarcijonas; Beatriz Luna; Deepak K Sarpal Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2019-01-30
Authors: Deepak K Sarpal; Delbert G Robinson; Christina Fales; Todd Lencz; Miklos Argyelan; Katherine H Karlsgodt; Juan A Gallego; Majnu John; John M Kane; Philip R Szeszko; Anil K Malhotra Journal: Neuropsychopharmacology Date: 2017-03-15 Impact factor: 7.853
Authors: Kim T Mueser; Min Kim; Jean Addington; Susan R McGurk; Sarah I Pratt; Donald E Addington Journal: Schizophr Res Date: 2016-10-15 Impact factor: 4.939